The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metastatic or recurrent pancreatic cancer.
Sun Jin Sym
No relevant relationships to disclose
Junsik Hong
No relevant relationships to disclose
Minkyu Jung
No relevant relationships to disclose
Yang Seo Koo
No relevant relationships to disclose
Yeon Ho Park
No relevant relationships to disclose
Koen Kook Kim
No relevant relationships to disclose
Jinny Park
No relevant relationships to disclose
Eun Kyung Cho
No relevant relationships to disclose
Jae Hoon Lee
No relevant relationships to disclose
Dongbok Shin
No relevant relationships to disclose